Breast cancer and aging: results of the U13 conference breast cancer panel M. F. BarginearH. MussA. Hurria Review 22 May 2014 Pages: 1 - 6
A retrospective study evaluating a fixed low dose capecitabine monotherapy in women with HER-2 negative metastatic breast cancer Tadeu AmbrosSimon B. ZeichnerCharles L. Vogel Review 05 June 2014 Pages: 7 - 14
Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer S. MuenstA. R. SchaerliS. D. Soysal Preclinical study 20 May 2014 Pages: 15 - 24
Hypomethylation of the MMP7 promoter and increased expression of MMP7 distinguishes the basal-like breast cancer subtype from other triple-negative tumors Steven T. SizemoreGina M. SizemoreRuth A. Keri Preclinical study 22 May 2014 Pages: 25 - 40
The metastatic potential of triple-negative breast cancer is decreased via caloric restriction-mediated reduction of the miR-17~92 cluster Lianjin JinMeng LimNicole L. Simone Preclinical study 27 May 2014 Pages: 41 - 50
Cholesterol biosynthesis inhibitors as potent novel anti-cancer agents: suppression of hormone-dependent breast cancer by the oxidosqualene cyclase inhibitor RO 48-8071 Yayun LiangCynthia Besch-WillifordSalman M. Hyder Preclinical study 31 May 2014 Pages: 51 - 62
A multi-institutional study on the association between BRCA1/BRCA2 mutational status and triple-negative breast cancer in familial breast cancer patients Moon-Woo SeongKyu Hyung KimSung-Won Kim Preclinical study 04 June 2014 Pages: 63 - 69
Obatoclax analog SC-2001 inhibits STAT3 phosphorylation through enhancing SHP-1 expression and induces apoptosis in human breast cancer cells Chun-Yu LiuJung-Chen SuKuen-Feng Chen Preclinical study 06 June 2014 Pages: 71 - 84
HITS-CLIP reveals key regulators of nuclear receptor signaling in breast cancer Manoj M. PillaiAustin E. GillenPeter Kabos Preclinical study 07 June 2014 Pages: 85 - 97
Inhibition of histone demethylase, LSD2 (KDM1B), attenuates DNA methylation and increases sensitivity to DNMT inhibitor-induced apoptosis in breast cancer cells Tiffany A. KatzShauna N. VasilatosYi Huang Preclinical study 13 June 2014 Pages: 99 - 108
A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI A. LintermansK. Van AstenP. Neven Clinical Trial 11 May 2014 Pages: 109 - 116
Quality of life and patient satisfaction after microsurgical abdominal flap versus staged expander/implant breast reconstruction: a critical study of unilateral immediate breast reconstruction using patient-reported outcomes instrument BREAST-Q Chunjun LiuYan ZhuangGordon K. Lee Clinical Trial 15 May 2014 Pages: 117 - 126
Early myocardial deformation abnormalities in breast cancer survivors Ben F. BultenAnnelies M. C. Mavinkurve-GroothuisLivia Kapusta Clinical Trial 23 May 2014 Pages: 127 - 135
Use of dried blood spots for the determination of serum concentrations of tamoxifen and endoxifen N. G. L. JagerH. RosingS. C. Linn Clinical Trial 25 May 2014 Pages: 137 - 144
A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer Yifan TuDawn L. HershmanJoseph A. Sparano Clinical trial 06 June 2014 Pages: 145 - 152
Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study Mark J. ClemonsBrandy CochraneMark N. Levine Clinical trial 13 June 2014 Pages: 153 - 162
Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis Dharanija MadhavanMarkus WallwienerBarbara Burwinkel Epidemiology 17 May 2014 Pages: 163 - 174
Outcome of triple negative breast cancer: comparison of sporadic and BRCA1-associated cancers Nadine TungElizabeth GaughanJudy E. Garber Epidemiology 18 May 2014 Pages: 175 - 182
Overweight and obesity as poor prognostic factors in locally advanced breast cancer patients C. Arce-SalinasJ. L. Aguilar-PonceA. Mohar Epidemiology 20 May 2014 Pages: 183 - 188
Body mass index, diabetes, and triple-negative breast cancer prognosis Sarah TaitJose M. PachecoCynthia X. Ma Epidemiology 29 May 2014 Pages: 189 - 197
The influence of diabetes severity on receipt of guideline-concordant treatment for breast cancer Susan A. SabatinoTrevor D. ThompsonRoger T. Anderson Epidemiology 05 June 2014 Pages: 199 - 209
Somatic mutation load of estrogen receptor-positive breast tumors predicts overall survival: an analysis of genome sequence data Svasti HaricharanMatthew N. BainbridgePowel H. Brown Brief Report Open access 18 May 2014 Pages: 211 - 220
Mortality outcome among medically underserved women screened through a publicly funded breast cancer control program, 1997–2007 Soumitra Sudip BhuyanJim P. StimpsonGe Lin Brief Report 06 June 2014 Pages: 221 - 227
Sentinel lymph node identification rates and axillary concordance can only be accurately determined by comparing ‘like with like’ injected materials Muneer Ahmed Letter to the Editor 31 May 2014 Pages: 229 - 230
Determining axillary concordance rate for different injection locations in sentinel node mapping of breast cancer: how ambitious can we get? Ramin SadeghiMehdi AsadiDavid N. Krag Rebuttal Letter 31 May 2014 Pages: 231 - 232
Erratum to: The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis Josh J. CarlsonJoshua A. Roth Erratum 08 June 2014 Pages: 233 - 233
